tetano
Editor, Senior Moderator
Front Immunol
. 2023 Mar 22;14:1147991.
doi: 10.3389/fimmu.2023.1147991. eCollection 2023.
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review
Aleksandra Zielińska[SUP] 1 [/SUP], Piotr Eder[SUP] 2 [/SUP], Jacek Karczewski[SUP] 3 [/SUP], Marlena Szalata[SUP] 4 [/SUP], Szymon Hryhorowicz[SUP] 1 [/SUP], Karolina Wielgus[SUP] 5 [/SUP], Milena Szalata[SUP] 6 [/SUP], Agnieszka Dobrowolska[SUP] 2 [/SUP], Atanas G Atanasov[SUP] 7 8 9 [/SUP], Ryszard Słomski[SUP] 1 [/SUP], Eliana B Souto[SUP] 10 11 [/SUP]
Affiliations
Abstract
Commonly used clinical strategies against coronavirus disease 19 (COVID-19), including the potential role of monoclonal antibodies for site-specific targeted drug delivery, are discussed here. Solid lipid nanoparticles (SLN) tailored with tocilizumab (TCZ) and loading cannabidiol (CBD) are proposed for the treatment of COVID-19 by oral route. TCZ, as a humanized IgG1 monoclonal antibody and an interleukin-6 (IL-6) receptor agonist, can attenuate cytokine storm in patients infected with SARS-CoV-2. CBD (an anti-inflammatory cannabinoid and TCZ agonist) alleviates anxiety, schizophrenia, and depression. CBD, obtained from Cannabis sativa L., is known to modulate gene expression and inflammation and also shows anti-cancer and anti-inflammatory properties. It has also been recognized to modulate angiotensin-converting enzyme II (ACE2) expression in SARS-CoV-2 target tissues. It has already been proven that immunosuppressive drugs targeting the IL-6 receptor may ameliorate lethal inflammatory responses in COVID-19 patients. TCZ, as an immunosuppressive drug, is mainly used to treat rheumatoid arthritis, although several attempts have been made to use it in the active hyperinflammatory phase of COVID-19, with promising outcomes. TCZ is currently administered intravenously. It this review, we discuss the potential advances on the use of SLN for oral administration of TCZ-tailored CBD-loaded SLN, as an innovative platform for managing SARS-CoV-2 and related infections.
Keywords: COVID-19; cannabidiol (CBD); cytokine storm; oral drug therapy; solid lipid nanoparticles (SLN); tocilizumab (TCZ).
. 2023 Mar 22;14:1147991.
doi: 10.3389/fimmu.2023.1147991. eCollection 2023.
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review
Aleksandra Zielińska[SUP] 1 [/SUP], Piotr Eder[SUP] 2 [/SUP], Jacek Karczewski[SUP] 3 [/SUP], Marlena Szalata[SUP] 4 [/SUP], Szymon Hryhorowicz[SUP] 1 [/SUP], Karolina Wielgus[SUP] 5 [/SUP], Milena Szalata[SUP] 6 [/SUP], Agnieszka Dobrowolska[SUP] 2 [/SUP], Atanas G Atanasov[SUP] 7 8 9 [/SUP], Ryszard Słomski[SUP] 1 [/SUP], Eliana B Souto[SUP] 10 11 [/SUP]
Affiliations
- PMID: 37033914
- PMCID: PMC10073701
- DOI: 10.3389/fimmu.2023.1147991
Abstract
Commonly used clinical strategies against coronavirus disease 19 (COVID-19), including the potential role of monoclonal antibodies for site-specific targeted drug delivery, are discussed here. Solid lipid nanoparticles (SLN) tailored with tocilizumab (TCZ) and loading cannabidiol (CBD) are proposed for the treatment of COVID-19 by oral route. TCZ, as a humanized IgG1 monoclonal antibody and an interleukin-6 (IL-6) receptor agonist, can attenuate cytokine storm in patients infected with SARS-CoV-2. CBD (an anti-inflammatory cannabinoid and TCZ agonist) alleviates anxiety, schizophrenia, and depression. CBD, obtained from Cannabis sativa L., is known to modulate gene expression and inflammation and also shows anti-cancer and anti-inflammatory properties. It has also been recognized to modulate angiotensin-converting enzyme II (ACE2) expression in SARS-CoV-2 target tissues. It has already been proven that immunosuppressive drugs targeting the IL-6 receptor may ameliorate lethal inflammatory responses in COVID-19 patients. TCZ, as an immunosuppressive drug, is mainly used to treat rheumatoid arthritis, although several attempts have been made to use it in the active hyperinflammatory phase of COVID-19, with promising outcomes. TCZ is currently administered intravenously. It this review, we discuss the potential advances on the use of SLN for oral administration of TCZ-tailored CBD-loaded SLN, as an innovative platform for managing SARS-CoV-2 and related infections.
Keywords: COVID-19; cannabidiol (CBD); cytokine storm; oral drug therapy; solid lipid nanoparticles (SLN); tocilizumab (TCZ).